IRLAB is granted additional patent for drug candidate mesdopetam
IRLAB is granted additional patent for drug candidate mesdopetam that expands its patent protection
Gothenburg, Sweden, September 4, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company has been granted a new patent in Europe, which includes a new salt of mesdopetam used throughout the clinical development process and the process of its preparation. The patent that has now been granted extends the already strong patent protection for mesdopetam, the company’s most advanced project.
“The already strong patent protection for mesdopetam is now expanded with a patent, EP3976581B1, which protects the active pharmaceutical ingredient of mesdopetam used in clinical development. With the extended protection, there is potential to extend market exclusivity for mesdopetam right up to the early 2040s, which is incredibly positive for the value of mesdopetam,” said Kristina Torfgård, CEO of IRLAB.
Mesdopetam has a vast clinical potential for unmet medical needs in Parkinson’s disease. The drug candidate is intended to treat people with Parkinson’s who develop levodopa induced dyskinesias (PD-LIDs), which is more than 30 percent of all people living with Parkinson’s. This equates to more than 1.5 million affected individuals in the eight major markets worldwide.
Mesdopetam has previously been granted a family of substance patents in all major markets worldwide. The newly approved patent covers a salt of mesdopetam which is used in the formulations in the ongoing clinical development. The patent expires in 2040. With the potential grant of a supplementary protection certificate (SPC) exclusivity can reach into the early 2040s.
Latest Posts
- US-Israeli Strikes on Iran LIVE Updates March 05, 2026 | Senate Fails To Curb Trump War Powers
March 5, 2026 | Breaking News, Live Updates, Politics, World - Is Pakistan Ready to Step In as Middle East Tensions Escalate with Saudi Arabia?
March 4, 2026 | Featured by VoM, Politics, World - Meta Blocks Kashmir Life, Greater Kashmir & Rising Kashmir Social Media Pages ; Political Leaders Condemn Restriction
March 4, 2026 | Breaking News, Jammu Kashmir - Following The Assassination Of Ayatollah Ali Khamenei, Mojtaba Khamenei Elected As New Supreme Leader of Iran
March 4, 2026 | Featured by VoM, Politics, World - US Has Bombed at Least 10 Countries Since 9/11 — And the Count Keeps Growing in 2026
March 4, 2026 | Featured by VoM, Politics, World - Iran’s Regional Attacks – A Broader Strategy Designed To Expand Pressure On The Global Stage, Beyond the Battlefield
March 4, 2026 | Articles/Editorials, Breaking News, Featured by VoM - LIVE Updates: Russia and China Condemn US‑Israeli Attacks on Iran, Call for Ceasefire
March 4, 2026 | Live Updates, Politics, World - No Trade With Spain says, US President Donald Trump, After Spain Restricted Military Bases
March 4, 2026 | Breaking News, Politics, World - UN Nuclear Chief Rafael Grossi Says No Evidence of Coordinated Iranian Weapons Program
March 3, 2026 | Breaking News, Politics, World - At Least 40 Killed, 246 Wounded in Lebanon Amid Escalating Israel-US Attacks on Iran
March 3, 2026 | Breaking News, Politics, World